ECLIPSE: A Phase III trial of Lutetium radioligand for mCRPC

Treatment of prostate cancer has changed dramatically over the years, with  multiple treatment options including chemotherapy, refined hormonal therapies, radiotherapies, surgery and others currently available, depending on the patient and their disease.

Dr Sakir Mutevelic, Chief Medical Officer at Curium, has witnessed the tremendous progress in cancer treatment options and the increased survival rate that goes with them.  Today, we’re talking with him about an investigational treatment for metastatic castration resistant prostate cancer in development at Curium, that could be a valuable new asset in disease management.

Information for clinicians about the Eclipse trial is available here.

For patients, a web portal with more information is available here.

All trial data is available at:  https://clinicaltrials.gov/ct2/show/NCT05204927